Recombinant shingles vaccine

Recombinant shingles vaccine has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Mar 4, 2026: “Infection, vaccination and risk of dementia: a proposed immunological model”.

Intervention

1 paper studies it1 findingUpdated

See all 1 papers on recombinant shingles vaccine

What is recombinant shingles vaccine linked with?

1

Studies link recombinant shingles vaccine with dementia.

Dementia

downin humans1

1 study
  1. Recombinant shingles vaccine lowers the risk of dementia in humans.

    “Over the last few years, the AS01-adjuvanted recombinant shingles vaccine has also been associated with reduced risk in several studies.”

    Review

    Infection, vaccination and risk of dementia: a proposed immunological model

    Frontiers in immunology

More on Dementia

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months